A Single-Arm, Open-Label, Dose-Escalation and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FXS887 in Patients With Advanced Solid Tumors
Latest Information Update: 29 Jan 2026
At a glance
- Drugs FXS 887 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Fosun Pharmaceutical Development
Most Recent Events
- 29 Jan 2026 New trial record